Insider-Owned Growth Companies To Watch In June 2024

As global markets navigate through mixed economic signals, with some indices reaching record highs amid fluctuating bond yields and inflation concerns, investors continue to seek stable yet promising opportunities. High insider ownership in growth companies often signals strong confidence from those who know the business best, making such stocks particularly interesting in these complex market conditions.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Cettire (ASX:CTT)	28.7%	29.9%
Global Tax Free (KOSDAQ:A204620)	18.1%	72.4%
KebNi (OM:KEBNI B)	37.8%	90.4%
Credo Technology Group Holding (NasdaqGS:CRDO)	15.2%	84.1%
Calliditas Therapeutics (OM:CALTX)	10.5%	52.9%
UTI (KOSDAQ:A179900)	34.1%	122.7%
EHang Holdings (NasdaqGM:EH)	33%	101.9%
La Française de l'Energie (ENXTPA:FDE)	20.1%	37.7%
HANA Micron (KOSDAQ:A067310)	19.8%	76.8%
OSE Immunotherapeutics (ENXTPA:OSE)	25.6%	79.3%

Click here to see the full list of 1471 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

D & O Green Technologies Berhad (KLSE:D&O)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: D & O Green Technologies Berhad, operating primarily through its subsidiary Dominant Opto Technologies Sdn Bhd, is engaged in the manufacturing and selling of automotive surface mount technology light emitting diodes across Asia, Europe, the United States, and other international markets, with a market capitalization of approximately MYR 5.99 billion.

Operations: The company generates revenue primarily from the semiconductor industry, totaling MYR 1.08 billion.

Insider Ownership: 19.2%

Revenue Growth Forecast: 14.1% p.a.

D & O Green Technologies Berhad has shown robust financial growth, with earnings increasing by 31.6% over the past year and forecasted annual earnings growth of 54.8%, significantly outpacing the Malaysian market's average. Despite its revenue growing at a slower pace than some peers, it still exceeds the market average. However, its projected Return on Equity in three years is relatively low at 13.4%. Recent results highlight substantial improvements with first quarter net income rising to MYR 11.28 million from MYR 0.863 million year-over-year, reflecting operational efficiency and market adaptation.

• Click to explore a detailed breakdown of our findings in D & O Green Technologies Berhad's earnings growth report.
• Our valuation report here indicates D & O Green Technologies Berhad may be overvalued.

Offcn Education Technology (SZSE:002607)

Simply Wall St Growth Rating: ★★★★★★

Overview: Offcn Education Technology Co., Ltd. is a multi-category vocational education provider in China, with a market capitalization of approximately CN¥11.59 billion.

Operations: The company's primary revenue of CN¥2.92 billion is derived from its education and training services.

Insider Ownership: 26.1%

Revenue Growth Forecast: 21.2% p.a.

Offcn Education Technology is poised for significant growth with expected annual revenue increases of 21.2% and earnings potentially growing by 65.33% per year. The company's forecast to turn profitable within three years, outpacing average market projections. However, its debt isn't well covered by operating cash flow, posing a financial challenge. Recent financials show a dip in quarterly revenue but a substantial rise in net income, indicating improving profitability despite fluctuating sales figures.

• Navigate through the intricacies of Offcn Education Technology with our comprehensive analyst estimates report here.
• The valuation report we've compiled suggests that Offcn Education Technology's current price could be inflated.

Shenzhen New Industries Biomedical Engineering (SZSE:300832)

Simply Wall St Growth Rating: ★★★★★★

Overview: Shenzhen New Industries Biomedical Engineering Co., Ltd. is a biomedical company that focuses on the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents for hospitals both domestically in the People's Republic of China and internationally, with a market capitalization of approximately CN¥58.79 billion.

Operations: The company generates revenue primarily from its in vitro diagnostic segment, which amounted to CN¥4.08 billion.

Insider Ownership: 18.9%

Revenue Growth Forecast: 22.3% p.a.

Shenzhen New Industries Biomedical Engineering Co., Ltd. has demonstrated robust financial performance with a substantial year-over-year increase in quarterly and annual revenues and net income, reflecting a strong growth trajectory. The company's earnings per share also saw significant growth. Despite its unstable dividend track record, the firm is trading slightly below fair value estimates and is expected to maintain high revenue and profit growth rates, outpacing the broader Chinese market forecasts. Insider trading activity has been neutral in recent months, indicating stable insider confidence amidst growth.

• Delve into the full analysis future growth report here for a deeper understanding of Shenzhen New Industries Biomedical Engineering.
• In light of our recent valuation report, it seems possible that Shenzhen New Industries Biomedical Engineering is trading beyond its estimated value.

Seize The Opportunity

• Click this link to deep-dive into the 1471 companies within our Fast Growing Companies With High Insider Ownership screener.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com